Accuracy and technical characteristics of CYP2C19 point of care tests: a systematic review
Authors:
Open Access
- 12 June 2024
- journal article
- review article
- Published by Taylor & Francis in Pharmacogenomics
- Vol. 25 (8-9) , 407-423
Abstract
Aim: To assess the accuracy and technical characteristics of CYP2C19 point of care tests (POCTs).Patients & methods: Systematic review of primary studies, in any population or setting, that evaluated POCTs for detecting CYP2C19 loss of function (LOF) alleles.Results: Eleven studies provided accuracy data (eight Spartan; one Genomadix Cube; one GMEX; one Genedrive). The POCTs had very high sensitivity and specificity for the alleles they tested for. Twenty-two studies reported technical characteristics: POCTs were easy to operate and provided results quickly. Limited data were reported for test failure rate and cost.Conclusion: CYP2C19 POCTs may be a useful alternative to laboratory-based testing to guide antiplatelet therapy. Further data are required on accuracy (GMEX; Genedrive), test failure and cost (all POCT).Keywords
Funding Information
- National Institute for Health Research (NIHR135620)
This publication has 50 references indexed in Scilit:
- Development of a routine bedside CYP2C19 genotype assessment program for antiplatelet therapy guidance in a community hospital catheterization laboratoryJournal of Thrombosis and Thrombolysis, 2024
- Clinical Pharmacogenetics Implementation Consortium Guideline for CYP2C19 Genotype and Clopidogrel Therapy: 2022 UpdateClinical Pharmacology & Therapeutics, 2022
- Cost Effectiveness of Genotype-Guided Antiplatelet Therapy in Asian Ischemic Stroke Patients: Ticagrelor as an Alternative to Clopidogrel in Patients with CYP2C19 Loss of Function MutationsClinical Drug Investigation, 2020
- PharmVar GeneFocus: CYP2C19Clinical Pharmacology & Therapeutics, 2020
- Prasugrel Versus Ticagrelor in Patients With CYP2C19 Loss-of-Function GenotypesJACC: Basic To Translational Science, 2020
- Revisiting the need for a literature search narrative: A brief methodological noteResearch Synthesis Methods, 2018
- Preemptive Panel-Based Pharmacogenetic Testing: The Time is NowPharmaceutical Research, 2017
- Characterization of Three CYP2C19 Gene Variants by MassARRAY and Point of Care Techniques: Experience from a Czech CentreArchivum Immunologiae et Therapiae Experimentalis, 2016
- Comparison of a rapid point-of-care and two laboratory-based CYP2C19*2 genotyping assays for personalisation of antiplatelet therapyInternational Journal of Clinical Pharmacy, 2016
- Resistance to clopidogrel: A review of the evidenceJACC, 2005